These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis. Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273 [TBL] [Abstract][Full Text] [Related]
5. Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis. Strandvik B; Malmborg AS; Bergan T; Michalsen H; Storrøsten OT; Wretlind B J Antimicrob Chemother; 1988 Apr; 21(4):471-80. PubMed ID: 3132441 [TBL] [Abstract][Full Text] [Related]
6. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial. Calandra GB; Hesney M; Brown KR Clin Ther; 1985; 7(2):225-38. PubMed ID: 3886144 [TBL] [Abstract][Full Text] [Related]
7. [Selection of resistant variants by broad spectrum beta-lactam antibiotics: to what extent is there cross resistance between imipenem and other beta-lactam antibiotics?]. Kahan F; Kropp H Immun Infekt; 1986 Nov; 14(6):232-5. PubMed ID: 3100429 [TBL] [Abstract][Full Text] [Related]
12. Antibacterial activity of imipenem: the first thienamycin antibiotic. Kropp H; Gerckens L; Sundelof JG; Kahan FM Rev Infect Dis; 1985; 7 Suppl 3():S389-410. PubMed ID: 3931196 [TBL] [Abstract][Full Text] [Related]
13. Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams. Lerner SA; Quinn JP Chemioterapia; 1985 Feb; 4(1):95-101. PubMed ID: 3921267 [TBL] [Abstract][Full Text] [Related]
14. Imipenem: the first thienamycin antibiotic. Williams RJ Postgrad Med J; 1986; 62 Suppl 2():75-7. PubMed ID: 3118345 [TBL] [Abstract][Full Text] [Related]
15. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925 [TBL] [Abstract][Full Text] [Related]
16. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of imipenem/cilastatin in patients with severe bacterial infections. Reutter FW J Antimicrob Chemother; 1986 Dec; 18 Suppl E():141-4. PubMed ID: 3469186 [TBL] [Abstract][Full Text] [Related]
18. Imipenem/cilastatin in the treatment of severe hospital infections. Patoia L; Menichetti F; Bucaneve G; Pasticci MB; Baratta E; Grignani F; Del Favero A Chemioterapia; 1988 Apr; 7(2):105-8. PubMed ID: 3165056 [TBL] [Abstract][Full Text] [Related]
19. Activity of imipenem against Pseudomonas and Bacteroides species. Williams JD Rev Infect Dis; 1985; 7 Suppl 3():S411-6. PubMed ID: 3931197 [TBL] [Abstract][Full Text] [Related]
20. Safe use of meropenem in a patient with a possible nonimmediate allergy to imipenem. Lakhal K; Lortat-Jacob B; Neukirch C; Pajot O; Wolff M Pharmacotherapy; 2007 Sep; 27(9):1334-8. PubMed ID: 17723087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]